T1	control 0 10	Aprepitant
T2	intervention 18 31	dexamethasone
T3	condition 47 82	chemotherapy-induced delayed emesis
T4	eligibility 655 751	chemotherapy-naive patients with breast cancer treated with anthracyclines plus cyclophosphamide
T5	outcome-Measure 1025 1124	rate of complete response (ie, no vomiting or rescue treatment) from days 2 to 5 after chemotherapy
T6	No-of-participants 1129 1132	580
T7	No-of-participants 1152 1155	551
T8	intervention-participants 1172 1175	273
T9	control-participants 1204 1207	278
T10	outcome 1229 1258	Day 1 complete response rates
T11	intervention-value 1273 1278	87.6%
T12	control-value 1301 1306	84.9%
T13	outcome 1338 1374	days 2 to 5, complete response rates
T14	outcome-Measure 1486 1585	complete protection, total control, no vomiting, no nausea, score of Functional Living Index-Emesis
T15	outcome 1597 1619	Incidences of insomnia
T16	intervention-value 1621 1625	2.9%
T17	control-value 1628 1632	0.4%
T18	outcome 1647 1656	heartburn
T19	intervention-value 1658 1662	8.1%
T20	control-value 1665 1669	3.6%
